Losartan Cost in Massachusetts 2026: Cash Pay, Insurance, Medicaid, and Compounding

What Does Losartan Actually Cost in Massachusetts Right Now?

Generic losartan is one of the least expensive prescription medications available at Massachusetts pharmacies in 2026. Cash prices at major chains such as CVS, Walgreens, Rite Aid, and Stop & Shop typically land between $8 and $14 per month for a 30-day supply of the 50 mg tablet, the most commonly prescribed starting dose. The Merck brand Cozaar carries a list price near $80 per month, but virtually no patient fills the brand name once generics are available.

The price gap between brand and generic is substantial. Merck received FDA approval for losartan potassium (Cozaar) in 1995, making it the first angiotensin II receptor blocker (ARB) approved in the United States [1]. Generic competition began around 2010, and the resulting price compression means that a 90-day supply at a warehouse retailer like Costco or BJ's can cost less than $15 total.

Discount platforms such as GoodRx, RxSaver, and NeedyMeds can push prices even lower. A 30-day supply of losartan 50 mg was available at selected Massachusetts zip codes for as little as $4 to $7 using a free coupon at specific pharmacies in early 2026. Prices shift monthly, so checking the platform directly before filling is always advisable.

Price by Dose Strength

| Dose | Typical 30-day cash price (MA, 2026) | |------|--------------------------------------| | 25 mg | $8 to $12 | | 50 mg | $9 to $14 | | 100 mg | $10 to $16 | | Losartan/HCTZ 50/12.5 mg | $12 to $18 | | Losartan/HCTZ 100/25 mg | $14 to $20 |

Prices vary by pharmacy, zip code, and whether you use a discount coupon. The table above reflects observed cash-pay ranges across the Greater Boston, Worcester, and Springfield markets.

Does Massachusetts Medicaid (MassHealth) Cover Losartan?

MassHealth covers losartan for its FDA-approved indications, but the formulary requires a prior authorization (PA) in most MassHealth plan types as of 2026. This PA requirement exists because MassHealth prefers certain ACE inhibitors (lisinopril, enalapril) as first-line antihypertensives given their lower acquisition cost. Losartan remains the drug of choice when a patient cannot tolerate an ACE inhibitor due to cough or angioedema, and the PA process for that clinical rationale is generally straightforward.

The MassHealth Drug List, updated quarterly, places losartan on the Non-Preferred tier under the ARB class. Your prescriber must submit clinical documentation confirming either ACE-inhibitor intolerance or an indication where ARBs are preferred (for example, diabetic nephropathy with Type 2 diabetes, per the ADA Standards of Care [2]). A complete PA request typically resolves within 72 hours for standard reviews and 24 hours for urgent clinical requests under MassHealth rules.

MassHealth members who qualify for the Low Income Subsidy (LIS, also called Extra Help) and use Medicare Part D alongside MassHealth pay $0 to $3.95 per month for Tier 1 generics like losartan under the 2026 LIS copay schedule.

Tips for a Successful MassHealth PA for Losartan

A well-constructed PA should include the patient's current blood pressure readings, the documented reason ACE inhibitors are not appropriate (dry cough affects roughly 10 to 15% of ACE-inhibitor users, with higher rates in Asian-American patients [3]), and any relevant lab data such as urine albumin-to-creatinine ratio (UACR) if diabetic nephropathy is the indication. Submitting these proactively rather than waiting for the PA to be returned incomplete cuts approval time significantly.

Which Commercial Insurance Plans Cover Losartan in Massachusetts?

Most commercial plans sold on the Massachusetts Health Connector or offered through employers place generic losartan on Tier 1 of their formulary. Tier 1 generics under Massachusetts-regulated plans typically carry a $0 to $10 copay per 30-day fill, and many plans allow a 90-day mail-order supply for a single copay, effectively reducing the monthly cost further.

Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Fallon Health all listed generic losartan as a Tier 1 preferred generic in their 2026 formulary documents reviewed by the HealthRX medical team. Aetna and UnitedHealthcare plans sold in Massachusetts similarly tier the generic favorably. Brand-name Cozaar is non-preferred or excluded on nearly every commercial formulary, reflecting the availability of therapeutically equivalent generics.

Patients with a high-deductible health plan (HDHP) who have not met their deductible may still pay cash prices at the pharmacy, making GoodRx or a manufacturer discount card relevant even for insured patients during the early months of a plan year.

Is Compounded Losartan Legal in Massachusetts?

Compounded losartan prepared by a Massachusetts-licensed 503A pharmacy is legal, provided the compounding meets the clinical criteria for patient-specific compounding under state and federal law. 503A pharmacies compound for individual patients based on a valid prescription; they operate under both Massachusetts Board of Pharmacy regulations and the federal Drug Quality and Security Act (DQSA) of 2013 [4].

Because FDA-approved generic losartan tablets are commercially available and inexpensive, the bar for clinical justification for compounded losartan is higher than for drugs without a generic equivalent. Situations where compounding may be clinically appropriate include:

• Swallowing difficulty: Pediatric patients or adults with dysphagia who need a liquid suspension formulation not commercially available in adequate dosing options.
• Allergy to a tablet excipient: Documented hypersensitivity to a specific inactive ingredient (such as microcrystalline cellulose or colorants) present in all commercially available tablet formulations.
• Custom dose titration: Rare cases requiring doses that fall outside the 25 mg to 100 mg tablet range.

A 503A compounding pharmacy cannot produce losartan in bulk for general sale; each preparation must be patient-specific with a valid prescription. Some specialty telehealth platforms operating in Massachusetts have arrangements with 503A pharmacies that supply compounded losartan suspensions at little or no direct cost to the patient, reducing out-of-pocket expense to approximately $0 per month in those programs.

The HealthRX clinical team uses the following three-step framework when evaluating whether a Massachusetts patient is a candidate for compounded losartan rather than a commercial generic tablet:

1. Confirm commercial tablet is inadequate. Document the specific clinical reason (dysphagia, excipient allergy, dose not achievable with tablets) with objective evidence in the chart.
2. Verify the 503A pharmacy's Massachusetts licensure. The Massachusetts Board of Pharmacy maintains a public licensee lookup at mass.gov. Confirm the pharmacy's license is active and includes sterile or non-sterile compounding as appropriate.
3. Assess cost and adherence impact. If the compounded formulation materially improves adherence (for example, a once-daily liquid is more reliably taken than a tablet the patient struggles to swallow), document that clinical rationale to support ongoing prescribing and potential insurance reimbursement requests.

Can You Get a Losartan Prescription via Telehealth in Massachusetts?

Telehealth prescribing of losartan is fully permitted in Massachusetts in 2026. Massachusetts enacted permanent telehealth parity legislation (Chapter 260 of the Acts of 2020, extended and made permanent through subsequent legislation) requiring commercial insurers to reimburse telehealth visits at parity with in-person visits [5]. This means a patient can have a video or phone consultation with a licensed Massachusetts prescriber, receive a losartan prescription, and have it sent electronically to any licensed Massachusetts pharmacy.

The prescriber must hold an active Massachusetts license and must conduct a clinically appropriate evaluation before prescribing any antihypertensive. For losartan specifically, this means documenting blood pressure readings (from a home monitor, pharmacy kiosk, or prior in-person visit), reviewing contraindications (pregnancy, bilateral renal artery stenosis, hyperkalemia), and establishing a follow-up plan for labs including serum potassium and creatinine within 4 to 8 weeks of initiating therapy [6].

HealthRX operates as a licensed telehealth platform in Massachusetts. A clinician-supervised visit for hypertension management, including losartan prescription if appropriate, can be completed in 15 to 20 minutes from any location within the state.

Why Losartan? A Brief Clinical Summary

Losartan blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. The net effect is vasodilation, reduced fluid retention, and lower blood pressure. The drug is FDA-approved for three indications: hypertension, reduction of stroke risk in patients with hypertension and left ventricular hypertrophy (LVH), and diabetic nephropathy in Type 2 diabetes patients with elevated creatinine and proteinuria [1].

The LIFE Trial: Losartan's Landmark Evidence

The LIFE trial (Losartan Intervention For Endpoint Reduction in Hypertension, N=9,193) published in The Lancet in 2002 compared losartan to atenolol in patients with hypertension and LVH [7]. Over a mean follow-up of 4.8 years, losartan reduced the composite endpoint of cardiovascular death, myocardial infarction, and stroke by 13% relative to atenolol (p = 0.021), with equivalent blood pressure lowering. The difference was driven primarily by a 25% relative risk reduction in fatal and nonfatal stroke in the losartan group. The trial authors concluded: "Losartan was significantly more effective than atenolol in reducing cardiovascular morbidity and mortality as well as all-cause mortality in patients with hypertension and ECG-documented LVH, despite similar reduction in blood pressure" [7].

This evidence underpins the ACC/AHA Hypertension Guidelines preference for ARBs in patients with hypertension plus LVH, Type 2 diabetes with CKD, or those intolerant to ACE inhibitors [8].

Dosing at a Glance

Losartan is initiated at 25 mg to 50 mg once daily in most patients. The dose may be titrated to 100 mg once daily after 3 to 6 weeks if blood pressure remains above target. In patients with diabetic nephropathy, trials used doses up to 100 mg daily. For patients on diuretics or with volume depletion, starting at 25 mg reduces the risk of first-dose hypotension. Losartan/hydrochlorothiazide (HCTZ) combination tablets (50/12.5 mg or 100/25 mg) are available generically at similarly low prices and improve adherence by consolidating two medications into one tablet.

The Cheapest Way to Get Losartan in Massachusetts: A Side-by-Side Comparison

Patients sometimes pay more than necessary simply because they do not know all available options. The table below compares the main pathways for obtaining losartan in Massachusetts and their typical 2026 costs.

| Pathway | Monthly cost estimate | Notes | |---|---|---| | Cash pay, retail pharmacy | $8 to $16 | Varies by dose and pharmacy | | GoodRx or RxSaver coupon | $4 to $10 | Free to use; no insurance needed | | MassHealth (with approved PA) | $0 to $3.40 | PA required; ACE-intolerance documentation needed | | Commercial insurance, Tier 1 | $0 to $10 copay | 90-day mail order may reduce cost further | | Medicare Part D (LIS/Extra Help) | $0 to $3.95 | LIS tier 1 copay for 2026 | | 503A compounded formulation | $0 (selected telehealth programs) | Requires clinical justification for compounding | | Brand Cozaar, no insurance | ~$80 | Rarely appropriate given generic availability |

Massachusetts Losartan Discount Programs and Savings Cards

Merck Patient Assistance

Merck offers a patient assistance program (Merck Helps) for uninsured or underinsured patients who meet income eligibility criteria. Because brand Cozaar costs far more than generic losartan and the generic is therapeutically equivalent, the more practical route for most Massachusetts patients is using a free coupon on generic losartan rather than seeking brand assistance.

State Pharmacy Assistance Programs

Massachusetts does not operate a state-funded pharmaceutical assistance program specifically for working-age adults as of 2026. The Prescription Advantage program, which historically supplemented Medicare Part D, was restructured. Medicare-eligible Massachusetts residents should confirm current Prescription Advantage enrollment options through the Massachusetts Executive Office of Elder Affairs.

Community Health Center Sliding-Scale Programs

Federally Qualified Health Centers (FQHCs) in Massachusetts, including Codman Square Health Center, Dimock Health Center, and Greater Lawrence Family Health Center, participate in the 340B Drug Pricing Program. 340B-eligible patients filling losartan at an FQHC in-house pharmacy may pay $0 to $2 per fill regardless of insurance status, because 340B prices on generic medications can be extremely low [9].

GoodRx and NeedyMeds

Both GoodRx and NeedyMeds are free, do not require insurance, and can be used by any Massachusetts resident. GoodRx prices are location-specific; a search for "losartan 50 mg, Boston MA" in January 2026 returned prices as low as $6.38 at select pharmacies. Prices in western Massachusetts cities such as Springfield and Holyoke were comparable. Showing the coupon at the pharmacy counter (or sending it via text to the pharmacist) is all that is required.

Monitoring Requirements That Affect Total Cost of Care

Losartan is inexpensive as a tablet, but safe prescribing requires periodic lab monitoring that adds to the total cost of managing hypertension. The ACC/AHA 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommends checking serum creatinine, blood urea nitrogen, and electrolytes (particularly potassium) at baseline and 2 to 4 weeks after initiating or uptitrating an ARB, then at least annually in stable patients [8].

Hyperkalemia is the most clinically significant lab concern with losartan, occurring in roughly 1.5 to 3% of treated patients depending on baseline renal function and concomitant medications [10]. Patients with CKD stage 3b or higher (eGFR <45 mL/min/1.73 m²) or those on potassium-sparing diuretics, potassium supplements, or trimethoprim require more frequent monitoring.

In Massachusetts, a basic metabolic panel (BMP) at a major laboratory such as Quest or LabCorp costs $20 to $40 without insurance. Many commercial insurers and MassHealth cover annual BMP monitoring for patients on antihypertensives at no patient cost under preventive care provisions.

Contraindications and Who Should Not Take Losartan

Pregnancy is an absolute contraindication. Losartan (and all ARBs) carry a Black Box Warning for fetal toxicity; exposure during the second and third trimesters causes fetal renal dysplasia, oligohydramnios, and neonatal death [1]. Women of reproductive age should use effective contraception during losartan therapy and must stop the drug immediately if pregnancy is confirmed.

Other contraindications relevant to Massachusetts prescribers include:

• Concomitant aliskiren use in patients with diabetes or eGFR <60 mL/min/1.73 m²: Dual RAS blockade significantly increases risk of renal impairment, hyperkalemia, and hypotension without additional cardiovascular benefit, per the ONTARGET trial data [11].
• Known hypersensitivity to losartan or any component of the formulation.
• Bilateral renal artery stenosis or stenosis of a solitary kidney: ARB-induced efferent arteriolar dilation can cause acute kidney injury in these patients.

A history of ACE-inhibitor-induced angioedema is not a contraindication to losartan, though the risk of cross-reactivity exists (estimated at 5 to 17% in published case series [12]). Prescribers should counsel patients accordingly and ensure they have emergency access to epinephrine if prescribed losartan after ACE-inhibitor angioedema.

Drug Interactions Relevant to Massachusetts Patients

Losartan is primarily metabolized by CYP2C9 to its active metabolite E-3174, which is five to forty times more potent as an AT1 blocker than the parent compound. CYP2C9 inhibitors (such as fluconazole, amiodarone, and high-dose fluvastatin) may increase losartan exposure and reduce formation of the active metabolite, with complex net effects on blood pressure [13]. CYP2C9 inducers (rifampin) can reduce losartan efficacy.

NSAIDs, including over-the-counter ibuprofen and naproxen widely available at Massachusetts pharmacies, can blunt the antihypertensive effect of losartan and increase the risk of acute kidney injury, particularly in elderly or volume-depleted patients. This interaction is underappreciated and worth reviewing at each visit [8].